Investigational drug · Phase 3
HRS-8427
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP), Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP).
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
7
Any phase or sponsor naming "HRS-8427"
First trial start
2024
Sep 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-8427", any sponsor or status.
Conditions studied
As listed on its trial records.
- Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
- Hospital-acquired Bacterial Pneumonia (HABP)
- Ventilator-associated Bacterial Pneumonia (VABP)
Approved drugs for the same conditions: Urinary tract infection · Pneumonia · Infectious disease and vaccines · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-8427" as an intervention, largest first.
- A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06569056 · 579 participants · Start Sep 25, 2024 · Primary completion Sep 1, 2026
Drug: HRS-8427; Imipenem and Cilastatin Sodium and 2 more · For: Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
Sites: Shanghai, China
- A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute PyelonephritisPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06144060 · 126 participants (planned) · Start Dec 2023 · Primary completion Jun 2024
Drug: HRS -8427; Imipenem and Cilastatin Sodium · For: Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
- A Trial of HRS-8427 in the Treatment of Adults With Bacterial PneumoniaPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06841731 · 120 participants · Start Apr 10, 2025 · Primary completion Sep 22, 2026
Drug: HRS-8427; Meropenem · For: Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP)
Sites: Beijing, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07070375 · 33 participants · Start Apr 19, 2023 · Primary completion Aug 23, 2023
Drug: HRS-8427 · For: Gram-negative Bacterial Infections
Sites: Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07073157 · 24 participants · Start Jul 15, 2025 · Primary completion Aug 15, 2025
Drug: HRS-8427 injection plus furosemide; HRS-8427 injection plus metformin · For: Health Volunteer
Sites: Fuzhou, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07049107 · 14 participants · Start Jun 23, 2025 · Primary completion Jul 21, 2025
Drug: HRS-8427 · For: Health Volunteer
Sites: Changsha, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07049562 · 6 participants · Start May 21, 2025 · Primary completion Jun 18, 2025
Drug: HRS-8427 · For: Healthy Cninese Adult Male
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects.
Yin T, Qu B, Zhang Q, et al. · Antimicrob Agents Chemother 2026
- Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram-negative bacterial infections.
Wu Y, Han Q, Yang H, et al. · Antimicrob Agents Chemother 2026
- Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects.
Cao Y, Huang Y, Xie J, et al. · Antimicrob Agents Chemother 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.